UroGen Pharma

UroGen Pharma

URGN· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock +119.9% in FY2025

Elizabeth Barrett is the CEO of UroGen Pharma and was paid $4.3M in FY2025 (Dec), up 4%.

Pay$100 in the stock at the end of FY21 → $246
CEO pay is from each UroGen Pharma proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives3

See all
  1. 1Elizabeth BarrettFY2025
  2. 2Jason SmithFY2025
  3. 3Mark P. Schoenberg, M.D.FY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

UroGen Pharma paid its 3 named executives $6.7M in total in FY2025 (Dec). CEO Elizabeth Barrett was paid $4.3M of that.

Name
Elizabeth BarrettChief Executive Officer
Jason SmithGeneral Counsel and Chief Compliance Officer
Mark P. Schoenberg, M.D.Chief Medical Officer

of each named executive, from the Summary Compensation Table of each proxy.

Peers18

See all

The FY2025 (Dec) proxy of UroGen Pharma names 18 peer companies for pay. Among UroGen Pharma and these peers, CEO pay was 6th highest of 7 and total shareholder return was the highest of 6.

6th highest of 7in UroGen Pharma and its pay peers, FY2025 (Dec) by CEO pay:

$2.8M$9.7M

1st highest of 6in UroGen Pharma and its pay peers, FY2025 (Dec) by total shareholder return:

$14$264

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board4

See all
  • Stuart Holden, M.D.Director · 10 yr on the boardIndependentAudit, Compliance—Paid as an executive
  • Cynthia ButittaDirector · 8 yr on the boardIndependentAudit (Chair)—Paid as an executive
  • Daniel G. WildmanDirector · 3 yr on the boardIndependentCompliance—Paid as an executive
  • James A. Robinson, JrDirector · 2 yr on the boardIndependentCompliance (Chair)—Paid as an executive

The board of the latest proxy (FY2025).

Activity

Filings6

See all
Proxy statementDEF 14AApr 30, 2026FY2025
Annual report10-KMar 2, 2026FY2025
Proxy statementDEF 14AJul 15, 2025FY2024
Annual report10-KMar 10, 2025FY2024
Proxy statementDEF 14AJul 1, 2024FY2023
Annual report10-KMar 14, 2024FY2023